Attribute preferences associated with gonadotropin-releasing hormone agonists/antagonists among women with endometriosis in the United States.

ABSTRACT:

Background

Endometriosis symptoms have multifaceted manifestations, and there are few approved nonsurgical treatment options. Gonadotropin-releasing hormone (GnRH) agonists/antagonists for endometriosis vary on efficacy, safety profile, and out-of-pocket (OOP) cost, among other features.

Objectives

This study quantified the importance that women with endometriosis in the United States (US) placed on pain and non-pain features that differ among these medications.

Design

English-speaking, 18 to 50 years (premenopausal) US women with healthcare coverage for the past 3 years, who self-reported a laparoscopy-confirmed endometriosis diagnosis, were recruited via healthcare research panels to complete a cross-sectional survey.

Methods

A discrete choice experiment (DCE

SUBMITTER: Maculaitis MC 

PROVIDER: S-EPMC12415343 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature